Francesca Marassi, PhD, and her collaborators have received a $13 million National Institutes of Health grant to study misplaced calcified deposits that are a misunderstood factor in common diseases of aging, including age-related macular degeneration.
Faricimab is currently approved in more than 70 countries to treat nAMD and DME, with more than 1 million doses distributed globally, and Genentech will highlight its ophthalmology portfolio at the American Society of Retina Specialists annual meeting in Seattle.
The American Society of Retina Specialists is holding its 2023 annual meeting July 28 through August 1 at the Seattle Convention Center in downtown Seattle.
For visual recovery to occur, there must be photoreceptors left that can be rescued.
Andrew Lee, MD, Andrew Carey, MD, and Elizabeth Fortin, MD, sit down on this episode of the NeuroOp Guru to discuss neuro-ophthalmology, interprofessional eConsults, and whether they provide timely and valuable guidance
Take a look at a review of the highlights and hottest stories from Ophthalmology Times during the week of July 16, 2023.
Santen will receive an equity stake in Visiox as an upfront payment, and remains eligible to receive sales milestone payments, as well as royalties on net sales of omidenepag isopropyl ophthalmic solution in the United States.
New laser is designed to deliver low-energy treatment with ultrashort pulse duration.
According to the ASRS Research and Safety in Therapeutics Committee, ophthalmologists noted instances of intraocular inflammation (IOI) after the initial injection of pegcetacoplan.
Condition is linked to longer resolution times, worse outcomes
SriniVas R. Sadda, MD, discusses being president-elect of ARVO, as well as AI research being conducted at Doheny Eye Institute.
According to the company, the transaction includes U.S. and Canadian commercial rights to six therapeutics, including two non-prescription brands.
According to the company, initial interim Phase 2 efficacy data is expected to be presented in H1 2024. It also is expected to provide an update regarding Phase 3 pivotal trial plans in Q1 2024 after discussion with the FDA later this year.
A recent study demonstrates the safety and efficacy of treating eyes with cross-linking after keratoconus relapses following keratoplasty.
Lens is stable in capsular bag, less sensitive to misalignment.
A trial funded by the National Institutes of Health underscores need for more research to head off high myopia.
The complement system identifies and eliminates pathogens and dying cells, 3 pathways can activate the complement system—classical, lectin, and alternative—and their activation results in similar functions of opsonization, inflammation, and cell lysis.
Nominations for the 2023 awards will close July 31, 2023.
According to a study, the experimental eye drop treatment was twice as effective as the standard injection therapy at reducing swelling and improving blood flow within the retina of mice with RVO.
While these complications are rare, they require prompt diagnosis and management to prevent serious visual morbidity.
This certifies that the facility adheres to a comprehensive set of regulatory standards as set by the NABP to ensure safety of drugs and medical devices in the US.
Take a look at a review of the highlights and hottest stories from Ophthalmology Times during the week of July 9, 2023.
The London-based company will use regenerative medicine to fight ocular disease.
According to researchers at Duke University Medical Center, the tool demonstrates the potential for a non-invasive and inexpensive way to diagnose a common precursor of Alzheimer’s disease.
The company has completed evaluation on candidates and selected a single drug candidate to move forward into clinical trials.
The 2023 41st annual meeting of the American Society of Retina Specialists (ASRS) will run from Thursday, July 27 to Tuesday, August 1 in Seattle, a city filled with sightseeing, museums, and great food to explore.
